CRDF - Cardiff Oncology reports additional data from onvansertib combo trial in colorectal cancer

Cardiff Oncology (CRDF) drops 9% in premarket after announcing additional data from Phase 1b/2 trial and initial findings from its Expanded Access Program ((EAP)) launched in June 2020, evaluating onvansertib combined with the chemo regimen FOLFIRI and Avastin (bevacizumab), for the second-line treatment of patients with KRAS mutation-positive metastatic colorectal cancer (mCRC). Data were presented at the American Society Clinical Oncology Gastrointestinal Cancers Symposium.New data from Phase 1b portion showed that of the 12 evaluable patients, 5 (42%) achieved a partial response ((PR)); 4 patients had a confirmed PR; 1 patient went on to curative surgery; 1 patient with a non-confirmed PR discontinued the study due to an unrelated event.8 (67%) showed durable responses of 6+ months with a range from 6.1 to 13.7 months, lower than 73% of the patients with durable response according to earlier data announced in September last year.Initial findings from the company's EAP for onvansertib showed that 6 (66%) of the first 9

For further details see:

Cardiff Oncology reports additional data from onvansertib combo trial in colorectal cancer